<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">9174267</article-id><article-id pub-id-type="publisher-id">13094</article-id><article-id pub-id-type="doi">10.1038/s41598-022-13094-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluation and comparison of antibiotic susceptibility profiles of <italic>Streptomyces</italic> spp. from clinical specimens revealed common and region-dependent resistance patterns</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kotrbov&#x000e1;</surname><given-names>Lucie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lara</surname><given-names>Ana Catalina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Corretto</surname><given-names>Erika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Scharfen</surname><given-names>Josef</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ulmann</surname><given-names>V&#x000ed;t</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Pet&#x00159;&#x000ed;&#x0010d;kov&#x000e1;</surname><given-names>Kate&#x00159;ina</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Chro&#x00148;&#x000e1;kov&#x000e1;</surname><given-names>Alica</given-names></name><address><email>alica.chronakova@upb.cas.cz</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.418338.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2255 8513</institution-id><institution>Institute of Soil Biology, </institution><institution>Biology Centre Academy of Sciences of the Czech Republic, </institution></institution-wrap>Na S&#x000e1;dk&#x000e1;ch 7, 370 05 &#x0010c;esk&#x000e9; Bud&#x0011b;jovice, Czechia </aff><aff id="Aff2"><label>2</label>National Laboratory for Pathogenic Actinomycetes, Trutnov Regional Hospital, Gork&#x000e9;ho 77, 541 01 Trutnov, Czechia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.448234.d</institution-id><institution>Public Health Institute Ostrava, </institution></institution-wrap>Partyz&#x000e1;nsk&#x000e9; n&#x000e1;m&#x0011b;st&#x000ed; 2633/7, 702 00, Ostrava, Czechia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.4491.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 116X</institution-id><institution>Institute of Immunology and Microbiology, 1St Faculty of Medicine, </institution><institution>Charles University, </institution></institution-wrap> Studni&#x0010d;kova 7, 128 00 Prague, Czechia </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>12</volume><elocation-id>9353</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>5</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2022</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Notwithstanding the fact that streptomycetes are overlooked in clinical laboratories, studies describing their occurrence in disease and potential pathogenicity are emerging. Information on their species diversity in clinical specimens, aetiology and appropriate therapeutic treatment is scarce. We identified and evaluated the antibiotic susceptibility profile of 84 <italic>Streptomyces</italic> clinical isolates from the Czech Republic. In the absence of appropriate disk diffusion (DD) breakpoints for antibiotic susceptibility testing (AST) of <italic>Streptomyces</italic> spp., we determined DD breakpoints by correlation with the broth microdilution method and by the distribution of zone diameters among isolates. Correlation accuracy was high for 9 antibiotics, leading to the establishment of the most valid DD breakpoints for <italic>Streptomyces</italic> antibiotic susceptibility evaluation&#x000a0;so far. Clinical strains belonged to 17 different phylotypes dominated by a cluster of strains sharing the same percentage of 16S rRNA gene sequence identity with more than one species (<italic>S. albidoflavus</italic> group<italic>, S. hydrogenans, S. resistomycificus, S. griseochromogenes</italic>; 70% of isolates). AST results showed that <italic>Streptomyces</italic> exhibited intrinsic resistance to penicillin, general susceptibility to amikacin, gentamycin, vancomycin and linezolid, and high percentage of susceptibility to tetracyclines and clarithromycin. For the remaining antibiotics, AST showed inter- and intra-species variations when compared to available literature (erythromycin, trimethoprim-sulfamethoxazole), indicating a region-dependent rather than species-specific patterns.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Microbiology techniques</kwd><kwd>Antimicrobial therapy</kwd></kwd-group><funding-group><award-group><funding-source><institution>Academy of Sciences of the Czech Republic Strategy AV21</institution></funding-source><award-id>Diversity of life and health of ecosystems</award-id><award-id>Diversity of life and health of ecosystems</award-id><principal-award-recipient><name><surname>Kotrbov&#x000e1;</surname><given-names>Lucie</given-names></name><name><surname>Chro&#x00148;&#x000e1;kov&#x000e1;</surname><given-names>Alica</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Ministry of Healthcare of the Czech Republic</institution></funding-source><award-id>17-30091A</award-id><award-id>17-30091A</award-id><award-id>17-30091A</award-id><award-id>17-30091A</award-id><principal-award-recipient><name><surname>Lara</surname><given-names>Ana Catalina</given-names></name><name><surname>Corretto</surname><given-names>Erika</given-names></name><name><surname>Pet&#x00159;&#x000ed;&#x0010d;kov&#x000e1;</surname><given-names>Kate&#x00159;ina</given-names></name><name><surname>Chro&#x00148;&#x000e1;kov&#x000e1;</surname><given-names>Alica</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2022</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Despite the great contribution of <italic>Streptomyces</italic> to medicine as a source of many bioactive compounds (antibiotics, immunosuppressants, antifungals and antivirals), they also have a potentially dark side and can cause infections in humans. The most common infection caused by <italic>Streptomyces</italic> is actinomycetoma, an endemic disease associated with <italic>S</italic>. <italic>somaliensis</italic>, <italic>S</italic>. <italic>sudanensis</italic>, <italic>S</italic>. <italic>griseus</italic> and <italic>S. viridis</italic><sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref></sup>. In addition to mycetoma, <italic>Streptomyces</italic> can also cause rare invasive infections such as pulmonary infections, bacteremias, brain abscesses, peritonitis and other diseases, mainly in immunocompromised patients (reviewed in<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup>). New approaches using next generation sequencing have recently shown that <italic>Streptomyces</italic> are likely a common part of the human<sup><xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref></sup>. However, the role of clinical <italic>Streptomyces</italic> isolates of unknown aetiology reported in numerous studies<sup><xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref></sup> remains unclear. Indeed, many <italic>Streptomyces</italic> secondary metabolites exhibit harsh effects in vitro (strong cytotoxic and &#x003b2;-hemolytic activities) and can play a significant role in the human immune response<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Moreover, examination of the genome of <italic>Streptomyces</italic> sp. TR1341 isolated from the sputum of an elderly patient with a long history of respiratory problems revealed the presence of several genes for opportunistic colonization of human tissues and for the resistance to antibiotics<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Their significance as opportunistic pathogens, the presence and description of possible virulence factors, and antibiotic susceptibility in the context of antibiotic resistance determinant transmission remain to be investigated.</p><p id="Par3">The tendency to isolate streptomycetes from clinical specimens has increased in the last decade<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref></sup>. This may be due to increasing air pollution in industrial and agricultural areas (dust as a vector for <italic>Streptomyces</italic> spores), but also to a growing number of immunodeficient patients caused by extrinsic/external factors (e. g. HIV infection, immunosuppressive drugs, environmental toxins or malnutrition)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Nevertheless, streptomycetes are still neglected in clinical practice, due to a lack of awareness of their clinical relevance and probably due to difficulties associated with their growth characteristics, which complicates their isolation in clinical laboratories. <italic>Streptomyces</italic> are usually slow-growing bacteria that are rapidly overgrown by common respiratory microbiota during routine cultivations. To eliminate the fast-growing bacteria, some mycobacteriological laboratories decontaminate clinical specimens with N-Acetyl-L-Cysteine-Sodium Hydroxide (NALC-NaOH). However, the negative effects of NALC-NaOH on the recovery of mycobacteria and <italic>Nocardia</italic> spp. have been reported<sup><xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref></sup>. Reduction of <italic>Streptomyces</italic> population and species selection cannot be ruled out. Even if <italic>Streptomyces</italic> survive this crude decontamination step, they will most likely be considered as contaminants, since microscopic identification requires an experienced person<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>.</p><p id="Par4">Because of the limited number of studies reporting antibiotic susceptibility profiles of clinical <italic>Streptomyces</italic>, with respect to the total of 674 <italic>Streptomyces</italic> species names validly published<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, antibiotic therapy against such infections is at best questionable. There is a consistent agreement that clinical <italic>Streptomyces</italic> isolates are susceptible to amikacin, gentamycin, vancomycin, and linezolid. In contrast, the vast majority of clinical isolates tested to date have been resistant to penicillin, the oldest known antibiotic. For the remaining antibiotics, there are differences in susceptibility patterns between species<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref></sup>. The results available in the literature suggest species-specific susceptibility, but the number of species-identified clinical isolates is too small to draw a clear conclusion.</p><p id="Par5">The key to predicting the clinical success or failure of a therapy is the antibiotic susceptibility test (AST), i.e., the in vitro response of the pathogen to selected antibiotics. The interpretive criteria to categorize an organism as susceptible (S), intermediate (I) or resistant (R)<sup><xref ref-type="bibr" rid="CR35">35</xref></sup> are clinical breakpoints. In addition to clinical breakpoints that guide therapy, the concept of epidemiological cut-off values (ECOFF) has been also defined. The ECOFF value serves as threshold for detecting bacteria with resistance mechanisms and for monitoring the evolution of resistance among isolates of the same bacterial species. This value divides a given bacterial population into a wild type group and a group with acquired or mutational resistance to a given drug<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>.</p><p id="Par6">The golden standard in AST is the broth microdilution method (BM). As a fast alternative with a lower cost serves disk diffusion method (DD). Since <italic>Streptomyces</italic> spp. are better adapted to growth on solid/semi-solid media<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>, DD method is more suitable for <italic>Streptomyces</italic> AST. While the DD method has been reported mainly in the characterization of environmental <italic>Streptomyces</italic><sup><xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref></sup>, its use in clinical setting is not excluded<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. However, given the lack of breakpoints for <italic>Streptomyces</italic> AST, the results of studies using DD method could be difficult to interpret or even misleading, increasing the likelihood of treatment failure.</p><p id="Par7">The objectives of the present study were: i) to perform a taxonomic classification based on the 16S rRNA gene of 84 clinical isolates of <italic>Streptomyces</italic> collected in Czech Republic, ii) to determine their antibiotic susceptibility profile using the DD method, iii) to evaluate the presence of acquired resistance mechanisms; and iv) to review antibiograms of clinical <italic>Streptomyces</italic> strains available in literature to discuss the suitability of the antibiotic therapy. Since the clinical breakpoints for the evaluation of the DD method results in <italic>Streptomyces</italic> or related organisms are not defined by an official scientific body, we attempted, for the first time, to correlate the DD results with the results of the broth microdilution (BM) techniques standardized by the Clinical and Laboratory Standard Institute (CLSI) for <italic>Streptomyces</italic> related organisms and to set appropriate DD breakpoints for antibiotic profiling of <italic>Streptomyces</italic> spp.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Bacterial isolates acquisition and identification</title><p id="Par8">The study included 84 non-duplicated human clinical isolates collected between 2009 and 2018 at the Trutnov Regional Hospital (29 strains, strain coding TR), the Ostrava Public Healthcare Institute (53 strains, strain coding OS), and the P&#x00159;&#x000ed;bram Regional Hospital (2 strains, strain coding PR). All strains were isolated during routine diagnostics in mycobacteriology laboratories. Strains have been deposited in the Collection of Actinomycetes of the Biology Centre Collection of Organisms (BCCO,&#x000a0;<ext-link ext-link-type="uri" xlink:href="http://www.actinomycetes.bcco.cz">www.actinomycetes.bcco.cz</ext-link>). DNA extraction and identification of all isolates was performed according to<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. The 16S rRNA gene sequences were compared against the type strains database using the Basic Local Alignment Search Tool<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. The phylogenetic tree was constructed using Geneious (v 8.1.6, <ext-link ext-link-type="uri" xlink:href="http://www.geneious.com">http://www.geneious.com</ext-link>, neighbour joining, Tamura-Nei genetic distance model, 1000 replicates). The strains were assigned to different clades according to<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. The list of all strains and the reference strains most closely related according to 16S rRNA gene similarity and their classification into clusters are reported in Table <xref rid="Tab1" ref-type="table">1</xref>. Strain TR1341 (here assigned to <italic>S. murinus</italic> based on nucleotide similarity of the 16S rRNA gene) was discussed in the previous study<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. The nucleotide sequences of the 16S rRNA genes of the isolates were deposited in GenBank under the accession numbers MZ393577-MZ393782 (Supplementary Table <xref rid="MOESM13" ref-type="media">S1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>List of clinical and soil isolates used in this study. The closest relative species according to 16S rRNA gene similarity referred as phylotype in this study, the clade assignment, number of strains included in the analysis for each category (Correlation of Minimum Inhibitory Concentrations (MIC) and Disk Diffusion (DD) zone diameter, Antibiotic Susceptibility Testing (AST)), and cluster assignment based on phylogeny analysis conducted in this study (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). ND &#x02013; not defined; * Labeda, D. P. et al. Phylogenetic study of the species within the family <italic>Streptomycetaceae</italic>. <italic>Antonie van Leeuwenhoek</italic>
<bold>101</bold>, 73&#x02013;104 (2012).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Strain ID</th><th align="left" rowspan="3">The closest relative species according to 16S rRNA gene similarity (phylotype)</th><th align="left" rowspan="3">Clade assignment<italic>*</italic></th><th align="left" colspan="4">No. of strains in analysis</th><th align="left" rowspan="3">Cluster assignment of clinical isolates based on phylogeny analysis</th></tr><tr><th align="left" colspan="3">Correlation MIC &#x02013; ZD zone diameter</th><th align="left">AST</th></tr><tr><th align="left">Clinical</th><th align="left">Soil</th><th align="left">Type strain</th><th align="left">Clinical</th></tr></thead><tbody><tr><td align="left">OS1529, OS2055, OS2660, OS8001, BCCO 10_1711</td><td align="left"><italic>S. carpaticus</italic></td><td align="left">Clade 128</td><td align="left">2</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">4</td><td align="left" rowspan="3">A (<italic>S. carpaticus</italic>)</td></tr><tr><td align="left">OS1126A</td><td align="left"><italic>S. ginkgonis</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td></tr><tr><td align="left">OS967, BCCO 10_1710</td><td align="left"><italic>S. xiamenensis</italic></td><td align="left">Clade 128</td><td align="left">1</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">1</td></tr><tr><td align="left">OS1127, OS282, OS1126 B</td><td align="left"><italic>S. albus</italic></td><td align="left">Clade 126</td><td align="left">2</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">3</td><td align="left">B (<italic>S. albus</italic>)</td></tr><tr><td align="left">OS17, OS18, OS20, OS21, OS32, 0S33, OS534, OS2864, OS2886A, OS3863, OS3889, OS4303, OS534, OS5590, OS5966, OS6152, OS6180, OS6215, OS6618, OS6629, OS6643, OS6672, OS6764, OS6783, OS6829, OS7188, OS7560, OS8079B, OS8305, OS8560, OS8619, OS8917, TR950, TR979, TR1008, TR1011, TR1048, TR1060, TR1135, TR1206, TR1247, TR1250, TR1349, TR1353, PR198, BCCO 10_0478, BCCO 10_0258, OS19, 0S22, 0S23, OS542, OS2243, OS3864, OS7748, OS8079A, OS10141, TR1041, TR1056, TR1059, TR1117, TR1134, TR1301, BCCO 10_1286, BCCO 10_0550</td><td align="left"><italic>S. albidoflavus</italic> group type strains<italic>/S. hydrogenans/S. resistomycificus/S. griseochromogenes</italic></td><td align="left">Clade 112</td><td align="left">13</td><td align="left">4</td><td align="left">&#x02013;</td><td align="left">59</td><td align="left">C (<italic>S. albidoflavus</italic>)</td></tr><tr><td align="left">TR1355, OS7207, TR1340, TR1147, TR1052</td><td align="left"><italic>S. gougerotii/S. rutgersensis/S. diastaticus</italic></td><td align="left">Clade 113</td><td align="left">3</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">5</td><td align="left" rowspan="2">D (<italic>S. gougerotii</italic>)</td></tr><tr><td align="left">OS6745</td><td align="left"><italic>S. intermedius/S. gougerotii/S. rutgersensis/S. diastaticus</italic></td><td align="left">Clade 113</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td></tr><tr><td align="left">TR1144</td><td align="left"><italic>S. thermoviolaceus</italic> subsp. <italic>apingens</italic></td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">E (<italic>S. thermoviolaceus</italic>)</td></tr><tr><td align="left">TR978</td><td align="left"><italic>S. drozdowiczii</italic></td><td align="left">Branch with clade 27</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">F (<italic>S. drozdowiczii</italic>)</td></tr><tr><td align="left">TR1341</td><td align="left"><italic>S. phaeogriseichromatogenes/S. murinus/S. griseofuscus</italic></td><td align="left">Clade 12</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">G (<italic>S. murinus</italic>)</td></tr><tr><td align="left">TR1292, BCCO 10_1719</td><td align="left"><italic>S. flavogriseus/S. flavovirens</italic></td><td align="left">Clade 37</td><td align="left">1</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left" rowspan="2">H (<italic>S. flavogriseus</italic>)</td></tr><tr><td align="left">TR1318</td><td align="left"><italic>S. flavofuscus/S. baarnensis/S. fimicarius/S. caviscabies</italic></td><td align="left">Branch with clade 35&#x02013;37</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td></tr><tr><td align="left">PR181</td><td align="left"><italic>S. seoulensis</italic></td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">I (<italic>S. seoulensis</italic>)</td></tr><tr><td align="left">OS587</td><td align="left"><italic>S. xylanilyticus</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">J (<italic>S. xylanilyticus</italic>)</td></tr><tr><td align="left">OS4451</td><td align="left"><italic>S. thermocarboxydus</italic></td><td align="left">Clade 109</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">K (<italic>S. thermocarboxydus</italic>)</td></tr><tr><td align="left">TR1049</td><td align="left"><italic>S. variabilis/S. griseoincarnatus/S. erythrogriseus</italic></td><td align="left">Clade 100</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">L (<italic>S. variabilis</italic>)</td></tr><tr><td align="left">TR1120</td><td align="left"><italic>S. plicatus/S. rochei/S. vinaceusdrappus/S. enissocaesilis</italic></td><td align="left">Clade 119</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">M (<italic>S. plicatus</italic>)</td></tr><tr><td align="left">BCCO 10_1622</td><td align="left"><italic>S. nanningensis</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">DSM 41685</td><td align="left"><italic>S. rameus</italic></td><td align="left">Clade 116</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1656</td><td align="left"><italic>S. sasae</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1683</td><td align="left"><italic>S. vinaceus/S. cirratus</italic></td><td align="left">Clade 39</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1638</td><td align="left"><italic>K. purpeofusca</italic></td><td align="left">Clade 57</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_0009</td><td align="left"><italic>S. arcticus</italic></td><td align="left">Clade 119</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1682</td><td align="left"><italic>S. wistariopsis</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_0501</td><td align="left"><italic>S. xanthochromogenes/S. mauvecolor/S. michiganensis</italic></td><td align="left">Clade 29</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1285</td><td align="left"><italic>S. pluricolorescens/S. globisporus/S. rubiginosohelvolus/S. mediolani</italic></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1665</td><td align="left"><italic>S. rishiriensis</italic></td><td align="left">Branch with clade 21</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1630</td><td align="left"><italic>S. acidiscabies</italic></td><td align="left">Clade 5</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">BCCO 10_1602</td><td align="left"><italic>S. noursei/S. albulus/S. yunnanensis</italic></td><td align="left">Clade 67</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">ND</td></tr><tr><td align="left">DSM 40783</td><td align="left"><italic>S. coelicolor</italic> A3(2)&#x02009;=&#x02009;<italic>S. violaceoruber</italic></td><td align="left">Clade 103</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">1</td><td align="left">&#x02013;</td><td align="left">ND</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>Antibiotic susceptibility testing</title><sec id="Sec5"><title>Antimicrobials</title><p id="Par9">The antimicrobials used in the study are listed in Table <xref rid="Tab2" ref-type="table">2</xref>. The abbreviations and disk contents are included.</p></sec><sec id="Sec6"><title>Disk diffusion test</title><p id="Par10"> Strains were grown on ISP3 medium<sup><xref ref-type="bibr" rid="CR44">44</xref></sup> prior AST at 36&#x000a0;&#x000b0;C (28&#x000a0;&#x000b0;C for soil isolates). The 0.5 McFarland suspension was prepared as described by CLSI in the M24 manual<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. A total of 200 &#x000b5;L of suspension was spread on Mueller&#x02013;Hinton agar 90-mm plates (Dulab, Dubn&#x000e9;, Czech Republic). Commercial antibiotic disks (Bio-Rad, Hercules, CA, USA) were used. Plates were incubated at 36&#x000a0;&#x000b0;C. Zones were measured after 24 or 48&#x000a0;h, depending on the growth rate of the strain. In the case of trimethoprim-sulfamethoxazole, slight growth within the zone was ignored as recommended in guidelines for broth microdilution method<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>.</p></sec><sec id="Sec7"><title>Clinical breakpoints setting</title><p id="Par11">To develop a criterion for interpreting DD results, we followed three different approaches. (1) To correlate DD with BM results for antibiotics available in a commercial BM kit. The minimum inhibitory concentration (MIC) breakpoints chosen to the derive zone diameter (ZD) breakpoints are reported in Table <xref rid="Tab2" ref-type="table">2</xref>. We selected 29 clinical isolates and the number of strains belonging to a given cluster was selected proportionately. To increase the robustness of the correlation analysis, 18 additional soil <italic>Streptomyces</italic> isolates (also deposited in BCCO) and the type strains <italic>S. rameus</italic> DSM 41685 and <italic>S. violaceoruber</italic> DSM 40783 were included in the study. The soil and type strains were subjected to the same procedures as the clinical isolates, except for the growth temperature, which was set to 28&#x000a0;&#x000b0;C. The soil isolates belonged to the same clusters as the clinical ones when possible. A total of 49 <italic>Streptomyces</italic> strains were used in the correlation analysis (Table <xref rid="Tab1" ref-type="table">1</xref>). (2) For antibiotics not available in a commercial BM kit, we proposed at least tentative breakpoints based on the distribution of the ZD data and the class of the antibiotic. (3) For antibiotics not available in a commercial BM kit and without a clear cut-off in the distribution of ZDs, we used arbitrary ZD breakpoints.</p></sec><sec id="Sec8"><title>Minimum inhibitory concentration (MIC) determinations</title><p id="Par12">The BM method for aerobic <italic>Actinomycetes</italic> described by CLSI in the M24 manual<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> was performed according to the guidelines. The commercial BM kits MIKROLATEST MIC&#x000ae; (Erba Lachema, Brno, Czech Republic) with dried antibiotics were used to determine MICs. Results were read after 72&#x000a0;h (optimal growth of all strains). The strains <italic>Enterococcus faecalis</italic> DSM 2570 and <italic>Escherichia coli</italic> DSM 1103 were used as quality control as recommended in BM kits guidelines.</p></sec><sec id="Sec9"><title>Data analysis</title><p id="Par13">Binary logarithms of the MIC values (mg/L) and average ZDs (mm) were calculated. Correlation between log MIC and average ZDs was tested using the Pearson correlation coefficient. The accuracy limit was set at r&#x02009;&#x0003e;&#x02009;0.75. Off-scale values were excluded. ZD interpretive susceptibility criteria were derived from the scattergrams of MIC endpoints and the ZD values followed by the error rate-bounded method<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. The discrepancy percentage between the correlated methods was calculated as very major error (VM; false-susceptible by disk diffusion), major error (M; false-resistant by disk diffusion) and minor error (m; one of the test results is intermediate and the other is susceptible or resistant). Epidemiological cut-off values (CO<sub>WT</sub>) to distinguish wild type and non-wild type populations (group with acquired or mutational resistance to that drug) were determined by automatic calculation for the zone distributions using the Normalized Resistance Interpretation<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> method for most the abundant species only. The obtained frequencies of resistant phenotypes were compared with those reported in a recent study<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> of clinical isolates from Spain. The concordance between resistance profiles for overlapping antibiotics was evaluated by Pearson&#x000b4;s chi-squared test (&#x003b1;&#x02009;=&#x02009;0.01). Only antibiotics with available MIC-DD correlation were included in the comparison (CIP, ERY and SXT). The frequency of resistance to the tested antibiotics, except those with arbitrary breakpoints (SMN, RIF and OFX), was calculated to determine multidrug resistance patterns of the clinical isolates.</p></sec><sec id="Sec10"><title>Review on available antibiograms</title><p id="Par14">Since the studies from clinical disciplines are presumed to use standardized methods for AST evaluation, we focused only on antibiograms reported for clinical <italic>Streptomyces</italic>. If MIC or ZD values were stated in studies<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR48">48</xref></sup>, we evaluated the susceptibility profile using the breakpoints cited or derived in our study.</p><p id="Par15">For more details about Material and Methods see Supplementary Text <xref rid="MOESM15" ref-type="media">S1</xref>.</p><p id="Par16">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Results of the correlation analysis between the standard broth microdilution method and the zone diameter distribution, and the results of AST of clinical isolates performed with the disk diffusion method.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" rowspan="3">Antimicrobials</th><th align="left" rowspan="3">Abbreviation</th><th align="left" rowspan="3">Disk content</th><th align="left" rowspan="2" colspan="3">Zone diameter breakpoints (mm)</th><th align="left" rowspan="2" colspan="3">MIC breakpoints (mg/L)</th><th align="left" colspan="4">Correlation parameters</th><th align="left" rowspan="2" colspan="3">% clinical isolates (<italic>n</italic>&#x02009;=&#x02009;<italic>84</italic>)</th><th align="left" rowspan="3">CO<sub>WT</sub> of cluster C&#x02009;&#x02265;&#x02009;(mm)</th></tr><tr><th align="left" rowspan="2">Pearson&#x000b4;s r</th><th align="left" colspan="3">No. of errors (%)</th></tr><tr><th align="left">R&#x02009;&#x02264;&#x02009;</th><th align="left">I</th><th align="left">S&#x02009;&#x02265;&#x02009;</th><th align="left">R</th><th align="left">I</th><th align="left">S</th><th align="left">VM</th><th align="left">M</th><th align="left">m</th><th align="left">R</th><th align="left">I</th><th align="left">S</th></tr></thead><tbody><tr><td align="left" rowspan="10">Zone diameter breakpoints corelated with MICs</td><td align="left">Ampicillin</td><td align="left">AMP</td><td align="left">10&#x000a0;&#x000b5;g</td><td align="left">21</td><td align="left">22&#x02013;24</td><td align="left">25</td><td align="left">&#x02265;&#x02009;16</td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;8<sup>A</sup></td><td align="left">&#x02212;0.96</td><td align="left">0</td><td align="left">0</td><td align="left">5(20)</td><td align="left">82</td><td align="left">6</td><td align="left">12</td><td align="left">11</td></tr><tr><td align="left">Amikacin</td><td align="left">AKN</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">30<sup>&#x02460;</sup></td><td align="left">&#x02265;&#x02009;16<sup>B</sup></td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;8<sup>B</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">100</td><td align="left">28<sup>&#x02462;</sup></td></tr><tr><td align="left">Chloramphenicol</td><td align="left">CMP</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">23</td><td align="left">24&#x02013;26</td><td align="left">27</td><td align="left">&#x0003e;&#x000a0;8<sup>C</sup></td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;8<sup>C</sup></td><td align="left">&#x02212;0.9</td><td align="left">2(7)</td><td align="left">0</td><td align="left">1(4)</td><td align="left">13</td><td align="left">2</td><td align="left">85</td><td align="left">24</td></tr><tr><td align="left">Ciprofloxacin</td><td align="left">CIP</td><td align="left">5&#x000a0;&#x000b5;g</td><td align="left">24</td><td align="left">25&#x02013;29</td><td align="left">30</td><td align="left">&#x02265;&#x02009;4<sup>B</sup></td><td align="left">2<sup>B</sup></td><td align="left">&#x02264;&#x02009;1<sup>B</sup></td><td align="left">&#x02212;0.89</td><td align="left">0</td><td align="left">0</td><td align="left">9(21)</td><td align="left">6</td><td align="left">46</td><td align="left">48</td><td align="left">26</td></tr><tr><td align="left">Erythromycin</td><td align="left">ERY</td><td align="left">15&#x000a0;&#x000b5;g</td><td align="left">22</td><td align="left">23&#x02013;28</td><td align="left">29</td><td align="left">&#x02265;&#x02009;8<sup>B</sup></td><td align="left">4<sup>B</sup></td><td align="left">&#x02264;&#x02009;2<sup>B</sup></td><td align="left">&#x02212;0.94</td><td align="left">0</td><td align="left">1(5)</td><td align="left">6(29)</td><td align="left">87</td><td align="left">7</td><td align="left">6</td><td align="left">9</td></tr><tr><td align="left">Gentamycin</td><td align="left">GEN</td><td align="left">10&#x000a0;&#x000b5;g</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">28<sup>&#x02460;</sup></td><td align="left">&#x02265;&#x02009;16<sup>A, D</sup></td><td align="left">8<sup>D, F</sup></td><td align="left">&#x02264;&#x02009;4<sup>A, D</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">100</td><td align="left">29</td></tr><tr><td align="left">Penicillin</td><td align="left">PEN</td><td align="left">10UI</td><td align="left">44</td><td align="left">45&#x02013;49</td><td align="left">50</td><td align="left">&#x0003e;&#x000a0;0.1252<sup>E</sup></td><td align="left">&#x02013;</td><td align="left">&#x02264; 0.12<sup>E</sup></td><td align="left">&#x02212;0.75</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">100</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left">Tetracycline</td><td align="left">TET</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">27</td><td align="left">28&#x02013;31</td><td align="left">32</td><td align="left">&#x0003e;&#x000a0;2<sup>E</sup></td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;2<sup>E</sup></td><td align="left">&#x02212;0.93</td><td align="left">0</td><td align="left">0</td><td align="left">2(29)</td><td align="left">8</td><td align="left">1</td><td align="left">91</td><td align="left">34</td></tr><tr><td align="left">Trimethoprim-sulfamethoxazole</td><td align="left">SXT</td><td align="left">1.25&#x000a0;&#x000b5;g&#x02009;+&#x02009;23.75&#x000a0;&#x000b5;g</td><td align="left">14</td><td align="left">&#x02013;</td><td align="left">15</td><td align="left">&#x02265;&#x02009;4/76<sup>B</sup></td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;2/38<sup>B</sup></td><td align="left">&#x02212;0.87</td><td align="left">0</td><td align="left">1(9)</td><td align="left">&#x02013;</td><td align="left">79<sup>&#x02461;</sup></td><td align="left">&#x02013;</td><td align="left">21<sup>&#x02461;</sup></td><td align="left">&#x02013;</td></tr><tr><td align="left">Vancomycin</td><td align="left">VAN</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">24<sup>&#x02460;</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;2<sup>D</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">100</td><td align="left">25</td></tr><tr><td align="left" rowspan="7">Tentative breakpoints according ZDs distribution</td><td align="left">Amoxicillin</td><td align="left">AMX</td><td align="left">25&#x000a0;&#x000b5;g</td><td align="left">27</td><td align="left">28&#x02013;30</td><td align="left">31</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">81</td><td align="left">6</td><td align="left">13</td><td align="left">18</td></tr><tr><td align="left">Amoxicillin-clavulanic acid</td><td align="left">AMC</td><td align="left">20&#x02009;&#x000b5;g&#x000a0;+&#x02009;10&#x000a0;&#x000b5;g</td><td align="left">20</td><td align="left">21&#x02013;22</td><td align="left">23</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">7</td><td align="left">6</td><td align="left">87</td><td align="left">20</td></tr><tr><td align="left">Cefazolin</td><td align="left">CZN</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">23</td><td align="left">24&#x02013;29</td><td align="left">30</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">98</td><td align="left">0</td><td align="left">2</td><td align="left">12</td></tr><tr><td align="left">Ceftriaxone</td><td align="left">CRO</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">23</td><td align="left">24&#x02013;29</td><td align="left">30</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">88</td><td align="left">5</td><td align="left">7</td><td align="left">10</td></tr><tr><td align="left">Clarithromycin</td><td align="left">CLR</td><td align="left">15&#x000a0;&#x000b5;g</td><td align="left">21</td><td align="left">22&#x02013;25</td><td align="left">26</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">7</td><td align="left">4</td><td align="left">89</td><td align="left">22</td></tr><tr><td align="left">Doxycycline</td><td align="left">DOX</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">27</td><td align="left">28&#x02013;31</td><td align="left">32</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">7</td><td align="left">1</td><td align="left">92</td><td align="left">35</td></tr><tr><td align="left">Minocycline</td><td align="left">MNO</td><td align="left">30&#x000a0;&#x000b5;g</td><td align="left">27</td><td align="left">28&#x02013;31</td><td align="left">32</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">4</td><td align="left">2</td><td align="left">94</td><td align="left">36</td></tr><tr><td align="left" rowspan="3">Arbitrary breakpoints</td><td align="left">Rifampicin</td><td align="left">RIF</td><td align="left">5&#x000a0;&#x000b5;g</td><td align="left">20</td><td align="left">21&#x02013;29</td><td align="left">30</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">11</td><td align="left">27</td><td align="left">62</td><td align="left">24<sup>&#x02462;</sup></td></tr><tr><td align="left">Streptomycin</td><td align="left">SMN</td><td align="left">10&#x000a0;&#x000b5;g</td><td align="left">20</td><td align="left">21&#x02013;29</td><td align="left">30</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">54</td><td align="left">39</td><td align="left">7</td><td align="left">11</td></tr><tr><td align="left">Ofloxacin</td><td align="left">OFX</td><td align="left">5&#x000a0;&#x000b5;g</td><td align="left">20</td><td align="left">21&#x02013;29</td><td align="left">30</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">17</td><td align="left">76</td><td align="left">7</td><td align="left">18</td></tr><tr><td align="left" rowspan="2">Only BM method performed</td><td align="left">Linezolid</td><td align="left">LIZ</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;8<sup>B</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">100<sup>&#x02463;</sup></td><td align="left">&#x02013;</td></tr><tr><td align="left">Ampicillin-sulbactam</td><td align="left">AMS</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02265;&#x02009;16</td><td align="left">&#x02013;</td><td align="left">&#x02264;&#x02009;8<sup>A</sup></td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td><td align="left">48<sup>&#x02463;</sup></td><td align="left">&#x02013;</td><td align="left">52<sup>&#x02463;</sup></td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>List of antibiotics, their abbreviations, and disk concentration used in the study are provided. Antibiotics are grouped into categories according to zone diameter breakpoint settings. Table shows the proposed zone diameter breakpoints based on ZD-MIC correlation analysis altogether with ZDs distribution among clinical strains, proposed MIC breakpoints according to available breakpoints values in CLSI and EUCAST guidelines and according to ZDs distribution among clinical strains. Parameters of the correlation analysis are provided: Pearson correlation coefficient (r), VM &#x02013; very major error, false-susceptible by DD; M &#x02013; major error, false-resistant by DD; m- minor error, one of the test results is intermediate and the other is susceptible or resistant. Antibiotic susceptibility distribution of clinical strains based on proposed ZD breakpoints and wild type cut-off (CO<sub>WT</sub>) calculated for clinical strains in the cluster C. Abbreviations: R = resistant, I = intermediate susceptible, S = susceptible; &#x02460; minimum ZD values were proposed as susceptibility breakpoints (type strain DSM 40783 was excluded for vancomycin and BCCO 10_1638 for amikacin), since predominantly susceptible strains (BM method) were present; &#x02461; only 78 clinical isolates were included, cluster D was excluded; &#x02462; abnormal standard deviation; &#x02463; only 29 clinical isolates were tested. References:&#x000a0;A&#x02014;Larruskain, J., Idigoras, P., Marim&#x000f3;n, J. M., P&#x000e9;rez-Trallero, E. Susceptibility of 186 <italic>Nocardia</italic> sp. isolates to 20 antimicrobial agents.<italic> Antimicrob. Agents. Chemother.</italic>
<bold>55</bold>, 2995&#x02013;8 (2011); B&#x02014;CLSI. Susceptibility testing of mycobacteria, and other aerobic actinomycetes. 2nd Ed. <italic>CLSI Guideline M24</italic> (2011); C&#x02014;Dragomirescu, C. C. <italic>et al.</italic> Antimicrobial susceptibility testing for <italic>Corynebacterium</italic> species isolated from clinical samples in Romania. <italic>Antibiotics</italic>
<bold>9</bold>, 1&#x02013;9 (2020); D&#x02014;CLSI. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd Ed. <italic>CLSI Guideline M45</italic> (2015); E&#x02014;EUCAST. Testing Breakpoint tables for interpretation of MICs and zone diameters. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_10.0_Breakpoint_Tables.pdf</ext-link> (2020).</p></table-wrap-foot></table-wrap>
</p></sec></sec></sec><sec id="Sec11"><title>Results</title><sec id="Sec12"><title>Strain taxonomy</title><p id="Par17">The selected 84 clinical <italic>Streptomyces</italic> strains belong to 16 different phylotypes (Table <xref rid="Tab1" ref-type="table">1</xref>). Most strains (83%) have the same percentage of sequence identity (PID) with more than one <italic>Streptomyces</italic> species due to insufficient variation in their 16S rRNA gene sequence (all clinical strains PID&#x02009;&#x0003e;&#x02009;99%, except OS587 with PID 98.88%). The phylogenetic tree of the clinical <italic>Streptomyces</italic> strains was complemented with environmental and type strains (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The clinical strains were then assigned to 13 phylogenetic clusters, with cluster C (<italic>S. albidoflavus</italic> group/<italic>S. hydrogenans</italic>/<italic>S. resistomycificus</italic>/<italic>S. griseochromogenes</italic>) comprising 70% of all clinical isolates.<fig id="Fig1"><label>Figure 1</label><caption><p>Neighbor-Joining tree of <italic>Streptomyces</italic> strains used in this study based on the 16S rRNA gene. Clinical isolates are highlighted in bold. Individual phylogenetic clusters are distinguished by colour and assigned letter codes. The 16S rRNA gene sequence of <italic>Nocardioides synnemataformans</italic> NBRC102581 served as the outgroup.</p></caption><graphic xlink:href="41598_2022_13094_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec13"><title>ZD breakpoints setting</title><p id="Par18">To derive ZD interpretive criterion, 3 different approaches were followed: i) Correlation of BM MICs values with zone diameters when antibiotics available in commercial BM kits; ii) Tentative breakpoints setting based on the distribution of ZD data and class of the antibiotic for antibiotics without correlation analysis; iii) Arbitrary ZD breakpoints when the distribution of ZDs did not reveal a clear cut-off for S-R category for antibiotics without correlation analysis.</p><sec id="Sec14"><title>Correlation analysis-based breakpoints</title><p id="Par19">We found a strong negative correlation (Pearson&#x000b4;s correlation r &#x002c2; &#x02212;0.89) between MIC and ZD values for AMP, ERY, TET, CMP, CIP, and PEN (&#x02212;0.96, &#x02212;0.94, &#x02212;0.93, &#x02212;0.90, &#x02212;0.89 and &#x02212;0.75, respectively). The proposed ZD breakpoints and the CO<sub>WT</sub> values are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. Discrepancy percentages of proposed breakpoints were in acceptable ranges. Scattergrams and discrepancy percentages are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> and Supplementary Figures S1&#x02013;S7. Evaluation of the correlation between MIC and ZD values for SXT was problematic due to difficulties in determining the MIC and ZD endpoints, which is likely reflected in a weak correlation (Pearson&#x000b4;s r&#x02009;=&#x02009;&#x02212;0.60, <italic>n</italic>&#x02009;=&#x02009;36, data not shown). In addition, strong disagreement between categories occurred in 27% of strains. This was partially resolved by prolonging the incubation in the DD method to 48&#x000a0;h. However, unsolved inconsistency persisted for cluster D strains (r&#x02009;=&#x02009;&#x02212;0.87 when cluster D strains were excluded). Incomplete interpretive breakpoints were proposed for VAN, GEN, and AKN, since only susceptible populations were available. Therefore, as ZD susceptibility breakpoints were chosen the minimum ZD values measured while susceptible by BM method.<fig id="Fig2"><label>Figure 2</label><caption><p>Ampicillin. Results of the correlation analysis of BM and DD methods followed by susceptibility testing of clinical isolates. (<bold>A</bold>) Scattergram comparing the results of broth microdilution MICs (mg/L) and zone diameters (mm) for 49 <italic>Streptomyces</italic> strains. The lines represent the proposed ZD interpretive criteria. (<bold>B</bold>) The table displays the number of tested isolates (n), very major error (VM), major error (M) and minor error (m). (<bold>C</bold>) The graph depicts the zone diameters distribution for 84 clinical <italic>Streptomyces</italic> strains. Dotted lines represent proposed zone diameter breakpoints (R&#x02014;resistant category, S&#x02014;susceptible category) and the CO<sub>WT</sub> value. Individual phylogenetic clusters are distinguished by colour. Based on the scattergram data, distribution of MICs and zone diameters, breakpoints were set as R&#x02009;&#x02264;&#x02009;18&#x000a0;mm, I&#x02009;=&#x02009;19&#x02013;24&#x000a0;mm and S&#x02009;&#x02265;&#x02009;25&#x000a0;mm, with no very major or major error and 4% of minor error (1 strain). However, when evaluating the zone size distribution of clinical strains, the CO<sub>WT</sub> of dominant cluster C was calculated to be 11&#x000a0;mm, indicating that the entire cluster C is resistant to ampicillin. Therefore, to minimise the risk of setting clinical breakpoints which split the resistant population (dominant cluster C) and in order to prevent misclassification of resistant strains as intermediate (I), we propose to use interpretive breakpoints as R&#x02009;&#x02264;&#x02009;21&#x000a0;mm, I&#x02009;=&#x02009;22&#x02013;24&#x000a0;mm, and S&#x02009;&#x02265;&#x02009;25&#x000a0;mm.</p></caption><graphic xlink:href="41598_2022_13094_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec15"><title>Breakpoints based on ZD data distribution and on antibiotic class</title><p id="Par20">The ZD distribution of CZN, CRO and CLR allowed us to visually define the R-S cut-offs, as most of the tested clinical <italic>Streptomyces</italic> strains were indisputably resistant (ZD 7&#x02013;20&#x000a0;mm) or susceptible (ZD more than 27&#x000a0;mm). The antibiotic class membership and similarity of MIC breakpoint values for unrelated genera (available in the AST guidelines) were considered for MNO, DOX, AMX and AMC (Supplementary Figures S8 and S9).</p></sec><sec id="Sec16"><title>Arbitrary ZD breakpoints</title><p id="Par21">The ZD distribution of DOX, OFX and SMN did not allow us to visually define the R-S cut-offs, and with the lack of MIC&#x02013;ZD correlation analysis, we arbitrarily defined the ZD breakpoint values as R&#x02009;&#x02264;&#x02009;20&#x000a0;mm, I&#x02009;=&#x02009;21&#x02013;29&#x000a0;mm, S&#x02009;&#x02265;&#x02009;30&#x000a0;mm (Supplementary Figure S10A-C).</p></sec></sec><sec id="Sec17"><title>Antibiotic susceptibility testing of clinical <italic>Streptomyces</italic> isolates</title><p id="Par22">The percentages of resistant, intermediate susceptible and susceptible strains are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. The CO<sub>WT</sub> values defining the cut-offs for the wild type and non-wild type population of the strains in cluster C are also shown in Table <xref rid="Tab2" ref-type="table">2</xref>. The resistance patterns of each <italic>Streptomyces</italic> phylotype and the assignment of the corresponding graphs are summarized in Table <xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Results of clinical isolates antibiotic susceptibility.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"><italic>Streptomyces</italic> phylotype</th><th align="left" rowspan="3">Cluster assignment based on phylogeny analysis</th><th align="left" rowspan="3">No. of strains</th><th align="left" colspan="10">No. of susceptible (intermediate susceptible) strains in group <sup>A</sup></th><th align="left" colspan="7">No. of susceptible (intermediate susceptible) strains in group <sup>B</sup></th><th align="left" colspan="3">No. of susceptible (intermediate susceptible) strains in group <sup>C</sup></th><th align="left" colspan="3">No. of susceptible (intermediate&#x000a0;susceptible) strains in group <sup>D</sup></th></tr><tr><th align="left">AMP</th><th align="left">CIP</th><th align="left">CMP</th><th align="left">ERY</th><th align="left">TET</th><th align="left">GEN</th><th align="left">PEN</th><th align="left">SXT</th><th align="left">AKN</th><th align="left">VAN</th><th align="left">AMX</th><th align="left">AMC</th><th align="left">CZN</th><th align="left">CRO</th><th align="left">CLR</th><th align="left">DOX</th><th align="left">MNO</th><th align="left">SMN</th><th align="left">RIF</th><th align="left">OFX</th><th align="left" rowspan="2">No. of strains</th><th align="left" rowspan="2">AMS</th><th align="left" rowspan="2">LIZ</th></tr><tr><th align="left">Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref></th><th align="left">Fig. S1</th><th align="left">Fig. S2</th><th align="left">Fig. S3</th><th align="left">Fig. S4</th><th align="left">Fig. S7</th><th align="left">Fig. S6</th><th align="left">Fig. S5</th><th align="left">Fig. S7</th><th align="left">Fig. S7</th><th align="left">Fig. S9</th><th align="left">Fig. S9</th><th align="left">Fig. S8</th><th align="left">Fig. S8</th><th align="left">Fig. S8</th><th align="left">Fig. S9</th><th align="left">Fig. S9</th><th align="left">Fig. S10</th><th align="left">Fig. S10</th><th align="left">Fig. S10</th></tr></thead><tbody><tr><td align="left"><italic>S. carpaticus</italic></td><td align="left">A</td><td align="left">4</td><td align="left">3(1)</td><td align="left">4</td><td align="left">0</td><td align="left">0</td><td align="left">4</td><td align="left">4</td><td align="left">0</td><td align="left">4</td><td align="left">4</td><td align="left">4</td><td align="left">4</td><td align="left">4</td><td align="left">0</td><td align="left">4</td><td align="left">0(1)</td><td align="left">4</td><td align="left">4</td><td align="left">0</td><td align="left">0(1)</td><td align="left">4</td><td align="left">2</td><td align="left">2</td><td align="left">2</td></tr><tr><td align="left"><italic>S. ginkgonis</italic></td><td align="left">A</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><italic>S. xiamenensis</italic></td><td align="left">A</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">0(1)</td><td align="left">0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><italic>S. albus</italic></td><td align="left">B</td><td align="left">3</td><td align="left">0</td><td align="left">1(2)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">3</td><td align="left">0</td><td align="left">3</td><td align="left">3</td><td align="left">3</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0(2)</td><td align="left">0</td><td align="left">0(1)</td><td align="left">2(1)</td><td align="left">0(1)</td><td align="left">0</td><td align="left">2</td><td align="left">0</td><td align="left">2</td></tr><tr><td align="left"><italic>S. hydrogenans/S. resistomycificus/S. griseochromogenes/S. albidoflavus</italic> group strains</td><td align="left">C</td><td align="left">59</td><td align="left">0</td><td align="left">26(32)</td><td align="left">57(2)</td><td align="left">0(4)</td><td align="left">58(1)</td><td align="left">59</td><td align="left">0</td><td align="left">0</td><td align="left">59</td><td align="left">59</td><td align="left">0(1)</td><td align="left">56(3)</td><td align="left">0</td><td align="left">0</td><td align="left">59</td><td align="left">59</td><td align="left">59</td><td align="left">0(24)</td><td align="left">40(16)</td><td align="left">0(55)</td><td align="left">13</td><td align="left">4</td><td align="left">13</td></tr><tr><td align="left"><italic>S. gougerotii/S. rutgersensis/S. diastaticus</italic></td><td align="left">D</td><td align="left">5</td><td align="left">1(4)</td><td align="left">4(1)</td><td align="left">5</td><td align="left">0</td><td align="left">5</td><td align="left">5</td><td align="left">0</td><td align="left">ND</td><td align="left">5</td><td align="left">5</td><td align="left">1(4)</td><td align="left">5</td><td align="left">0</td><td align="left">0</td><td align="left">5</td><td align="left">5</td><td align="left">5</td><td align="left">0(4)</td><td align="left">5</td><td align="left">0(5)</td><td align="left">3</td><td align="left">3</td><td align="left">3</td></tr><tr><td align="left"><italic>S. intermedius/S. gougerotii/S. rutgersensis/S. diastaticus</italic></td><td align="left">D</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">ND</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0(1)</td><td align="left">0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr><tr><td align="left"><italic>S. thermoviolaceus</italic>subsp. <italic>apingens</italic></td><td align="left">E</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"><italic>S. drozdowiczii</italic></td><td align="left">F</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td></tr><tr><td align="left"><italic>S. phaeogriseichromatogenes/S. murinus/S. griseofuscus</italic></td><td align="left">G</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0(1)</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"><italic>S. flavogriseus/S. flavovirens</italic></td><td align="left">H</td><td align="left">1</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"><italic>S. flavofuscus/S. baarnensis/S. fimicarius/S. caviscabies</italic></td><td align="left">H</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"><italic>S. seoulensis</italic></td><td align="left">I</td><td align="left">1</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"><italic>S. xylanilyticus</italic></td><td align="left">J</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"><italic>S. thermocarboxydus</italic></td><td align="left">K</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0(1)</td><td align="left">1</td><td align="left">0(1)</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td></tr><tr><td align="left"><italic>S. variabilis/S. griseoincarnatus/S. erythrogriseus</italic></td><td align="left">L</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0(1)</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td></tr><tr><td align="left"><italic>S. plicatus/S. rochei/S. vinaceusdrappus/S. enissocaesilis</italic></td><td align="left">M</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">1</td><td align="left">0</td><td align="left">0(1)</td><td align="left">0(1)</td><td align="left">0</td><td align="left">0</td><td align="left">0</td><td align="left">&#x02013;</td><td align="left">&#x02013;</td></tr></tbody></table><table-wrap-foot><p>Numbers represent the quantity of susceptible and intermediate susceptible (in the brackets) strains. Supplementary figures with details of the AST results are referred for each antibiotic. Abbreviations: ND &#x02013; not determined. Note:&#x000a0;<sup>A</sup>Breakpoints set by correlation analysis; <sup>B</sup>Breakpoints based on ZD data distribution and on class of antibiotic; <sup>C</sup>Arbitrary ZD breakpoints; <sup>D</sup>Only MIC values for 29 clinical strains; AMP &#x02013; ampicillin, CIP &#x02013; ciprofloxacin, CMP &#x02013; chloramphenicol, ERY &#x02013; erythromycin, TET &#x02013; tetracycline, GEN &#x02013; gentamycin, PEN &#x02013; penicillin, SXT &#x02013; trimethoprim-sulfamethoxazole, AKN &#x02013; amikacin, VAN &#x02013; vancomycin, AMX &#x02013; amoxicillin, AMC &#x02013; amoxicillin-clavulanic acid, CZN &#x02013; cefazolin, CRO &#x02013; ceftriaxone, CLR &#x02013; clarithromycin, DOX &#x02013; doxycycline, MNO &#x02013; minocycline, SMN &#x02013; streptomycin, RIF &#x02013; rifampicin, OFX &#x02013; ofloxacin, AMS &#x02013; ampicillin-sulbactam, LIZ &#x02013; linezolid.</p></table-wrap-foot></table-wrap></p><p id="Par23">A high percentage of resistant clinical strains was found in case of penicillin group antibiotics: PEN (100%), AMP (82%) and AMX (81%). The enrichment of AMX with clavulanic acid rapidly decreased the resistance of clinical isolates to 7%. A high resistance frequency was also found in case of CZN, CRO, ERY and SXT: 98%, 88%, 87% and 79%, respectively. In contrast, all clinical isolates were susceptible to AKN, GEN and VAN. A high frequency of susceptible clinical strains was found in case of tetracycline group antibiotics (MNO, DOX, TET), CLR, CMP and CIP: 94&#x02013;91%, 89%, 85% and 49% (plus 45% in &#x0201c;I&#x0201d; category), respectively. A high frequency of susceptible or intermediate susceptible clinical strains was also found for RIF (62% and 27% as &#x0201c;S&#x0201d; and &#x0201c;I&#x0201d; category) and OFX (7% and 76% as S and I category). However, due to the lack of reliable breakpoints (ZD breakpoints were set arbitrarily) these results need further validation. Within the tested cluster C strains, 3.4%, 3.4%, 6.7%, 8.5%, 1.7% and 1.7% were non-wild type in case of AMX, CZN, CIP, TET, DOX and VAN, respectively. For AKN and RIF, non-wild type populations were not determined, as the cluster C zone diameter datasets have an abnormal distribution. For the remaining tested antibiotics, all strains were wild types.</p><p id="Par24">For AMS and LIZ, we performed only the BM method and only 29 clinical isolates were included. All isolates were susceptible to LIZ. In case of AMS, the MIC values of 83% of tested clinical isolates decreased by 1 or more dilutions compared to the MIC value of AMP alone, i.e., the susceptibility of the strains increased (24% of clinical isolates changed susceptibility category from R to S).</p><p id="Par25">Most isolates were resistant to 7 drugs (53 isolates), with a minimum resistance to 1 drug (TR1144 resistant only to PEN) and with maximum multi-drug resistance to 12 drugs occurring in 2 isolates in cluster B (OS282 and OS1126B) and strain TR1341 of cluster G (Supplementary Figure S11).</p><p id="Par26">The comparison of AST results between clinical isolates of the same cluster (cluster C) collected in Spanish provinces (25 isolates)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> and those in our study (59 isolates) is shown on Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. The proportion of resistant isolates significantly differs by country for ERY (<italic>X</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;42.314; p &#x002c2; 0.01) and SXT (<italic>X</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;23.789; p &#x002c2; 0.01). The frequency of resistant isolates is 93% and 100% in Czech Republic compared to 24% and 64% in Spain, respectively. The proportion of resistant isolates does not differ for CIP (<italic>X</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0.401; p&#x02009;=&#x02009;0.818).<fig id="Fig3"><label>Figure 3</label><caption><p>The occurrence of resistant clinical isolates of cluster C in Czech Republic and Spain. Comparison of AST results preformed in this study with the ones reported in a recent study by<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. ERY - erythromycin, CIP - ciprofloxacin, SXT - trimethoprim-sulfamethoxazole.</p></caption><graphic xlink:href="41598_2022_13094_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec18"><title>Review on antibiograms</title><p id="Par27">Antibiograms of clinical <italic>Streptomyces</italic> available in the literature are summarized in Supplementary Table S2 (December 2021). We confirmed general susceptibility to AKN, GEN, VAN and LIZ, and resistance to PEN. For the remaining antibiotics, there are inter- and intra-species variations with unexplained drivers.</p></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par28">Although <italic>Streptomyces</italic> is increasingly emerging in clinical settings, there is little information on the aetiology, species distribution and antibiotic susceptibility profiles, with respect to the high number of <italic>Streptomyces</italic> species described to date. These are mostly case&#x000a0;reports<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR49">49</xref>&#x02013;<xref ref-type="bibr" rid="CR51">51</xref></sup>, with only scarce works addressing the large cohorts of clinical isolates<sup><xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref></sup>. Together with these, our work brings a new perspective on the presence and diversity of <italic>Streptomyces</italic> spp. in human microbiome, and points, that streptomycetes are important in clinical samples and should receive greater attention.</p><p id="Par29">Here we present identification and AST of 84 clinical <italic>Streptomyces</italic> isolates collected in Central Europe (Czech Republic). For the first time, we performed a correlation between the BM and DD method in AST of <italic>Streptomyces</italic>. Most of the strains in our study were isolated from patients suffering from chronic respiratory disease (59.5%), although it is not clear whether they were the cause of the disease, represented a secondary bacterial infection, or they were common colonizers of the human body. Although 17 different phylotypes were identified among the clinical <italic>Streptomyces</italic> in our study, only 3 of them have been reported as causative organisms of human diseases before: <italic>S. albus</italic> and <italic>S. thermoviolaceus</italic> in pulmonary&#x000a0;infections<sup><xref ref-type="bibr" rid="CR27">27</xref>,<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR52">52</xref></sup>, <italic>S. albus</italic> as a causative agent of mycetoma<sup><xref ref-type="bibr" rid="CR33">33</xref></sup> and <italic>S. thermocarboxydus</italic> in keratitis<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. A recent study<sup><xref ref-type="bibr" rid="CR14">14</xref></sup> identified 6 other phylotypes identical to those presented in our study (<italic>S. albidoflavus</italic>, <italic>S. rutgersensis</italic>, <italic>S. rochei</italic>, <italic>S. drozdowiczii</italic>, <italic>S. xylanilyticus</italic> and <italic>S. carpaticus</italic>), but their clinical relevance is unknown. The phylotypes reported in our study as clusters H, I, L, M, and <italic>S. ginkgonis</italic>, with <italic>S. xiamenensis</italic> of cluster A are associated with clinical specimens for the first time. It is interesting to note that cluster C, which is the most abundant in our study (70.2% of clinical isolates), has been reported only in another study so far, and moreover with much less proportion (~&#x02009;13% of clinical isolates)<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. This could be due to regional differences in agriculture, industry and lifestyle, that could play a role in the colonization of humans by different <italic>Streptomyces</italic> species, as well as due to complicated taxonomic issues. Taxonomy of <italic>Streptomyces</italic> species is a complex task involving the identification of genotypic and phenotypic characters<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. The sequences in the GenBank database are updated literally every minute, and therefore the reports on species identified decades ago are questionable (e. g. 28 <italic>Streptomyces</italic> isolates of <italic>S. griseus</italic><sup><xref ref-type="bibr" rid="CR12">12</xref></sup>) and thus difficult to compare.</p><p id="Par30">To evaluate the AST of <italic>Streptomyces</italic> spp. we chose the modified Kirby-Bauer method correlated with broth microdilution method (CLSI guidelines for <italic>Nocardia</italic> and other aerobic actinomycetes<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>) for 10 antibiotics. Since establishing clinical breakpoints is a challenging task, all available MIC breakpoints for <italic>Streptomyces</italic> spp. were selected as alternatives based on their taxonomic classification. If official MIC breakpoints for <italic>Streptomyces</italic> spp. are established by an international committee, the DD breakpoints proposed in this study can be easily adjusted using the scattergrams provided.</p><p id="Par31">The correlations were excellent for all tested antibiotics (Pearson&#x000b4;s correlation coefficient ranged from &#x02212;0.89 to &#x02212;0.96), except for PEN and SXT. <italic>Streptomyces</italic> species are known for their benzylpenicillin resistance<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>, thus all the strongly resistant values outside the MIC range (&#x0003e;&#x02009;8&#x000a0;mg/L) had to be excluded from the correlation calculation (28 strains). This might have led to less accurate results. In case of SXT, the inconsistency in reading the MIC endpoint occurred. Due to the uneven growth of streptomycetes in liquid cultures (growth in clumps), it is difficult to detect wells with partial growth (20% lower detection rate comparing to control well as recommended by CLSI) or determine a clear cut-off, while slight growth is neglected. Moreover, the unresolved disagreement between methods occurred in cluster D (<italic>S. gougerotii</italic>). Although SXT is recommended worldwide for the treatment of actinomycetoma<sup><xref ref-type="bibr" rid="CR56">56</xref></sup> as an empirical antibiotic therapy, we believe that the treatment of <italic>Streptomyces</italic> infections with SXT is probably inappropriate because of the low accuracy of the results as well as the high percentage of resistant strains in our study.</p><p id="Par32">The variability of the species in our study is limited and is mainly represented by cluster C strains (70.2%), which have the same or very similar resistance patterns. Considering the species-specific susceptibility profile of <italic>Streptomyces</italic><sup><xref ref-type="bibr" rid="CR57">57</xref></sup>, the notably high percentages of resistance to some antibiotics (AMP, SXT and ERY) may be biased by the large proportion of one phylotype in our data set. Therefore, we compared AST profiles from our study with those for clinical species previously published (Supplementary Table S2). Our data confirmed a general susceptibility of <italic>Streptomyces</italic> to AKN, GEN, VAN and LIZ. The only discrepancy found in the literature is a strain of <italic>S. griseus</italic> resistant to AKN with MIC of 16&#x000a0;mg/L<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> described as susceptible in the study, but resistant according to current guidelines<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. However, the result is questionable, since the AST procedures as well as the methods for identification have changed since the study was published (1990). These antibiotics are associated with the treatment of complicated multi-drug resistant infections and are often reserved as drugs of last resort, some of which have significant side effects<sup><xref ref-type="bibr" rid="CR58">58</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref></sup>. On the contrary, there is intrinsic resistance to PEN, usually recommended as first-line therapy for the treatment of respiratory diseases and pneumonia<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. For the remaining antibiotics, there is a considerable variability in the susceptibility profiles of <italic>Streptomyces</italic> spp., for some of them with high percentage of resistance (cephalosporins, CIP, ERY) or susceptibility (CLR, tetracyclines, imipenem). Thus, if antibiotic other than the safe one must be used, AST of the causative organism is recommended as well as species identification.</p><p id="Par33">The most interesting property of <italic>Streptomyces</italic> is their ability to produce antibiotics. Since antibiotic resistance genes are thought to originate from antibiotic-producing bacteria, the likelihood of multi-drug resistance (MDR) occurrence is high. For example, there are more than 100 drug resistance gene homologues in the chromosome of <italic>Streptomyces coelicolor</italic> A3(2)<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> and the presence of the Van cluster (<italic>vanSRJKHAX</italic>) associated with inducible resistance to vancomycin has been reported, too<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. Nevertheless, there are indications that most of the MDR systems are suppressed under laboratory conditions and <italic>Streptomyces</italic> species are therefore generally considered to be drug sensitive<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. In our study, we found strains with a wide range of resistance patterns, from generally susceptible to MDR strains. It is noteworthy that one of the most resistant clinical strains in our study, <italic>Streptomyces</italic> sp. TR1341, originated from a patient with multiorgan tuberculosis, relapsing respiratory infections and chronic obstructive pulmonary disease with a long-term and repeated antibiotic therapy<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. This phenotype was supported by genomic analysis, which revealed the presence of 41 known resistance models in its genome<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>.</p><p id="Par34">Even though non-wild type strains were found in clinical isolates of cluster C, there is no obvious shift in susceptibility category within strains of same phylotype. The ZD value of the only one non-wild type isolate of cluster C that changed susceptibility category compared to wild type isolates balances at the ZD breakpoint value. Therefore, our data suggest a rather species-specific susceptibility profile of <italic>Streptomyces.</italic> To confirm our findings, we compared the antibiograms of the cluster C strains with those presented in the only study on clinical isolates of <italic>S. albidoflavus</italic> (Spain) in the literature to date<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. All our isolates from cluster C were resistant to ERY and SXT, as reflected also in a low CO<sub>WT</sub> value in case of ERY (CO<sub>WT</sub> for SXT was not calculated since all strains lacked an inhibition zone). Contrary, only 24% of <italic>S. albidoflavus</italic> isolates from Spain were resistant to ERY. This discrepancy suggests local adaptation of the cluster C species to unique selection pressures in different regions, including differences in agriculture, industry, lifestyle, and also antibiotic and other drug policy (higher consumption of SXT and macrolides in Czech Republic compared to Spain)<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR68">68</xref></sup>. Spontaneous mutations conferring ERY-resistance under selection pressure have already been demonstrated in the model actinomycetes <italic>S. coelicolor</italic> and <italic>S. lividans</italic><sup><xref ref-type="bibr" rid="CR69">69</xref></sup> and are associated with point mutations in <italic>rrnA</italic>-23S rRNA&#x000a0;and <italic>rrnC</italic>-23S rRNA<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>. Since SXT resistance determinants are located on mobile elements such as small plasmids and gene cassettes<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>, horizontal gene transfer under appropriate conditions is a possibility, although it has not yet been documented for <italic>Streptomyces</italic>.</p><p id="Par35">In conclusion, we proved a generally high suitability and accuracy of the disk diffusion method for the AST of <italic>Streptomyces</italic> spp. by correlation with the gold-standard microdilution broth method for 9 antibiotics (SXT remains the questionable due to unresolved ambiguity in cluster D). This led to the determination of DD susceptibility breakpoints derived from MIC breakpoints for <italic>Streptomyces</italic>&#x02014;related organisms. To the best of our knowledge, these are the most valid DD breakpoints for <italic>Streptomyces</italic> reported to date. Tentative breakpoints have been proposed for 10 additional antibiotics, however, these breakpoints were designed primarily for the purpose of this study. Further analyses, such as correlation analyses, are recommended. All tested clinical isolates were susceptible to AKN, GEN, VAN and LIZ which is in agreement with literature, therefore these antibiotics can be chosen as empiric treatment for <italic>Streptomyces</italic>-associated infections. A low percentage of resistant isolates (&#x002c2; 10%) was found in our study for tetracyclines, CLR, CIP and AMC, however, data for CIP and AMC susceptibility differs in literature (Supplementary Table 2). In contrast, <italic>Streptomyces</italic> are intrinsically resistant to penicillin, and have a high percentage of resistance to cephalosporins. Other antibiograms (ERY and SXT) appear to be regionally driven, rather than species-specific and thus AST must be performed prior therapy. The treatment with ERY and SXT associates with a high risk of failure due to acquired resistance and should be reconsidered. Our study also emphasizes that <italic>Streptomyces</italic> are emerging in clinical practice, although still largely neglected, and points out the importance of optimizing techniques for selective isolation from clinical specimens. As awareness of streptomycetes infections in humans has increased, it is desirable to continue investigating their virulence factors and clinical relevance.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec20"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2022_13094_MOESM1_ESM.pdf"><caption><p>Supplementary Information 1.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41598_2022_13094_MOESM2_ESM.pdf"><caption><p>Supplementary Information 2.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41598_2022_13094_MOESM3_ESM.pdf"><caption><p>Supplementary Information 3.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="41598_2022_13094_MOESM4_ESM.pdf"><caption><p>Supplementary Information 4.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="41598_2022_13094_MOESM5_ESM.pdf"><caption><p>Supplementary Information 5.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="41598_2022_13094_MOESM6_ESM.pdf"><caption><p>Supplementary Information 6.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="41598_2022_13094_MOESM7_ESM.pdf"><caption><p>Supplementary Information 7.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="41598_2022_13094_MOESM8_ESM.pdf"><caption><p>Supplementary Information 8.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="41598_2022_13094_MOESM9_ESM.pdf"><caption><p>Supplementary Information 9.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="41598_2022_13094_MOESM10_ESM.pdf"><caption><p>Supplementary Information 10.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="41598_2022_13094_MOESM11_ESM.pdf"><caption><p>Supplementary Information 11.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM12"><media xlink:href="41598_2022_13094_MOESM12_ESM.xlsx"><caption><p>Supplementary Information 12.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM13"><media xlink:href="41598_2022_13094_MOESM13_ESM.xlsx"><caption><p>Supplementary Information 13.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM14"><media xlink:href="41598_2022_13094_MOESM14_ESM.xlsx"><caption><p>Supplementary Information 14.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM15"><media xlink:href="41598_2022_13094_MOESM15_ESM.docx"><caption><p>Supplementary Information 15.</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-022-13094-4.</p></sec><ack><title>Acknowledgements</title><p>This study was funded by the project of the Ministry of Healthcare of the Czech Republic (No. 17-30091A) and the Research Programme of the Academy of Sciences of the Czech Republic Strategy AV21 &#x0201c;Diversity of life and health of ecosystems&#x0201d; and &#x0201c;Land conservation and restoration&#x0201d;. Special thanks to MVDr. Petr Je&#x0017e;ek from P&#x00159;&#x000ed;bram Regional Hospital for providing clinical isolates. The authors thank V&#x000e1;clav Kri&#x00161;t&#x0016f;fek, Martina Petrl&#x000ed;kov&#x000e1;, Petra Ben&#x000ed;&#x00161;kov&#x000e1;, Nikola Fukov&#x000e1; and Franti&#x00161;ek Lorenc for technical support.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>L.K. and A.C. designed the research and coordinated the scientific activities; V.U. and J.S. organized and performed isolation of strains and initial genus recognition; L.K., A.C., A.C.L., E.C. and K.P. performed laboratory experiments and conducted DNA analyses; L.K. processed and evaluated data; L.K. and A.C. wrote the first draft and all authors contributed on writing the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par36">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chander</surname><given-names>J</given-names></name><name><surname>Singla</surname><given-names>N</given-names></name><name><surname>Handa</surname><given-names>U</given-names></name></person-group><article-title>Human cervicofacial mycetoma caused by <italic>Streptomyces griseus</italic>: First case report</article-title><source>J. Microbiol. Immunol. Infect.</source><year>2015</year><volume>48</volume><fpage>703</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2012.12.002</pub-id><pub-id pub-id-type="pmid">23465713</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borelli</surname><given-names>D</given-names></name><name><surname>Middelveen</surname><given-names>M</given-names></name></person-group><article-title>Actinomycetoma Caused by <italic>Streptomyces somaliensis</italic></article-title><source>Arch. Dermatol.</source><year>1986</year><volume>122</volume><fpage>1097</fpage><lpage>1098</lpage><pub-id pub-id-type="doi">10.1001/archderm.1986.01660220011002</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>BN</given-names></name><name><surname>Maiti</surname><given-names>PK</given-names></name><name><surname>Sil</surname><given-names>J</given-names></name></person-group><article-title>Antibiotic sensitivity patterns of actinomycetes isolated from patients of actinomycetoma</article-title><source>Indian J. Med. Res.</source><year>1997</year><volume>105</volume><fpage>162</fpage><lpage>166</lpage><?supplied-pmid 9145598?><pub-id pub-id-type="pmid">9145598</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quintana</surname><given-names>ET</given-names></name><etal/></person-group><article-title><italic>Streptomyces sudanensis</italic> sp. nov., a new pathogen isolated from patients with actinomycetoma</article-title><source>Antonie Van Leeuwenhoek</source><year>2008</year><volume>93</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1007/s10482-007-9205-z</pub-id><pub-id pub-id-type="pmid">18157699</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>NM</given-names></name><name><surname>Harish</surname><given-names>BN</given-names></name><name><surname>Sistla</surname><given-names>S</given-names></name><name><surname>Thappa</surname><given-names>DM</given-names></name><name><surname>Parija</surname><given-names>SC</given-names></name></person-group><article-title><italic>Streptomyces</italic> bacteremia in a patient with actinomycotic mycetoma</article-title><source>J. Infect. Dev. Ctries.</source><year>2010</year><volume>4</volume><fpage>249</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.3855/jidc.645</pub-id><pub-id pub-id-type="pmid">20440064</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbr&#x000ed;k</surname><given-names>A</given-names></name><etal/></person-group><article-title>A human lung-associated <italic>Streptomyces </italic>sp TR1341 produces various secondary metabolites responsible for virulence, cytotoxicity and codulation of immune response</article-title><source>Front. Microbiol.</source><year>2020</year><volume>10</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.03028</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>M</given-names></name><etal/></person-group><article-title><italic>Streptomyces</italic> pneumonia in an immunocompetent adult&#x02014;A rare isolate</article-title><source>Adv. Respir. Med.</source><year>2021</year><volume>89</volume><fpage>68</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.5603/ARM.a2020.0171</pub-id><pub-id pub-id-type="pmid">33471359</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>F</given-names></name><etal/></person-group><article-title>The initial state of the human gut microbiome determines its reshaping by antibiotics</article-title><source>ISME J.</source><year>2016</year><volume>10</volume><fpage>707</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1038/ismej.2015.148</pub-id><pub-id pub-id-type="pmid">26359913</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collado</surname><given-names>MC</given-names></name><name><surname>Rautava</surname><given-names>S</given-names></name><name><surname>Aakko</surname><given-names>J</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name></person-group><article-title>Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1038/srep23129</pub-id><pub-id pub-id-type="pmid">28442746</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YJ</given-names></name><etal/></person-group><article-title>The airway microbiome in patients with severe asthma: Associations with disease features and severity</article-title><source>J. Allergy Clin. Immunol.</source><year>2015</year><volume>136</volume><fpage>874</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2015.05.044</pub-id><pub-id pub-id-type="pmid">26220531</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X</given-names></name><etal/></person-group><article-title>16S rDNA analysis of periodontal plaque in chronic obstructive pulmonary disease and periodontitis patients</article-title><source>J. Oral Microbiol.</source><year>2017</year><volume>9</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.3923/mj.2019.1.7</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>MM</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Jarvis</surname><given-names>WR</given-names></name><name><surname>Ajello</surname><given-names>L</given-names></name></person-group><article-title>Comparison of species ditribution and antimicrobial susceptibility of aerobic actinomycetes from clinical specimens</article-title><source>Rev. Infect. Dis.</source><year>1990</year><volume>12</volume><fpage>778</fpage><lpage>783</lpage><pub-id pub-id-type="doi">10.1093/clinids/12.5.778</pub-id><pub-id pub-id-type="pmid">2237117</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rose</surname><given-names>CE</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Fisher</surname><given-names>JF</given-names></name></person-group><article-title>Brain abscess caused by <italic>Streptomyces</italic> infection following penetration trauma: Case report and results of susceptibility analysis of 92 isolates of <italic>Streptomyces</italic> species submitted to the CDC from 2000 to 2004</article-title><source>J. Clin. Microbiol.</source><year>2008</year><volume>46</volume><fpage>821</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1128/JCM.01132-07</pub-id><pub-id pub-id-type="pmid">18094128</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;ez-Nieto</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Identification and antimicrobial susceptibility of <italic>Streptomyces</italic> and other unusual <italic>Actinobacteria</italic> clinical isolates in Spain</article-title><source>New Microbes New Infect.</source><year>2021</year><volume>44</volume><fpage>100946</fpage><pub-id pub-id-type="doi">10.1016/j.nmni.2021.100946</pub-id><pub-id pub-id-type="pmid">34917388</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lara</surname><given-names>AC</given-names></name><etal/></person-group><article-title>The genome analysis of the human lung-associated <italic>Streptomyces</italic> sp. TR1341 revealed the presence of beneficial genes for opportunistic colonization of human tissues</article-title><source>Microorganisms</source><year>2021</year><volume>9</volume><fpage>1547</fpage><pub-id pub-id-type="doi">10.3390/microorganisms9081547</pub-id><pub-id pub-id-type="pmid">34442631</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahdar</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Molecular identification and antibiotic resistance pattern of actinomycetes isolates among immunocompromised patients in Iran, emerging of new infections</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41598-021-90269-5</pub-id><pub-id pub-id-type="pmid">33414495</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamid</surname><given-names>ME</given-names></name></person-group><article-title>Variable antibiotic susceptibility patterns among <italic>Streptomyces</italic> species causing actinomycetoma in man and animals</article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2011</year><volume>10</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1186/1476-0711-10-24</pub-id><pub-id pub-id-type="pmid">21232163</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoza</surname><given-names>AS</given-names></name><name><surname>Mfinanga</surname><given-names>SGS</given-names></name><name><surname>Moser</surname><given-names>I</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>B</given-names></name></person-group><article-title>Isolation, biochemical and molecular identification of <italic>Nocardia</italic> species among TB suspects in northeastern, Tanzania; A forgotten or neglected threat?</article-title><source>BMC Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1186/s12879-017-2520-8</pub-id><pub-id pub-id-type="pmid">28049444</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>L</given-names></name><etal/></person-group><article-title>Chronic suppurative otitis media due to <italic>Streptomyces cacaoi</italic>, the second case report in human infection</article-title><source>BMC Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>10</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s12879-020-05222-0</pub-id><pub-id pub-id-type="pmid">31906924</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinen</surname><given-names>J</given-names></name><name><surname>Shearer</surname><given-names>WT</given-names></name></person-group><article-title>Secondary immunodeficiencies, including HIV infection</article-title><source>J. Allergy Clin. Immunol.</source><year>2010</year><volume>125</volume><fpage>S195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.08.040</pub-id><pub-id pub-id-type="pmid">20042227</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>PR</given-names></name><name><surname>Heeren</surname><given-names>R</given-names></name><name><surname>Niles</surname><given-names>AC</given-names></name></person-group><article-title>Effect of decontamination procedures on recovery of <italic>Nocardia</italic> spp</article-title><source>J. Clin. Microbiol.</source><year>1987</year><volume>25</volume><fpage>2010</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1128/jcm.25.10.2010-2011.1987</pub-id><pub-id pub-id-type="pmid">3667923</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>S</given-names></name><name><surname>Chapagain</surname><given-names>M</given-names></name><name><surname>Gumbo</surname><given-names>T</given-names></name></person-group><article-title>Effect of specimen processing, growth supplement, and different metabolic population on <italic>Mycobacterium tuberculosis</italic> laboratory diagnosis</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mtafya</surname><given-names>B</given-names></name><etal/></person-group><article-title>Molecular bacterial load assay concurs withculture on NaOH-induced loss of <italic>Mycobacterium tuberculosis</italic> viability</article-title><source>J. Clin. Microbiol.</source><year>2019</year><volume>57</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1128/JCM.01992-18</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scharfen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Filamentous &#x02018;contaminants&#x02019; in the mycobacteriology laboratory; their culture, identification and clinical significance</article-title><source>Klin. Mikrobiol. Infekc. Lek.</source><year>2010</year><volume>16</volume><fpage>48</fpage><lpage>57</lpage><?supplied-pmid 20503156?><pub-id pub-id-type="pmid">20503156</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parte</surname><given-names>AC</given-names></name><name><surname>Carbasse</surname><given-names>JS</given-names></name><name><surname>Meier-Kolthoff</surname><given-names>JP</given-names></name><name><surname>Reimer</surname><given-names>LC</given-names></name><name><surname>G&#x000f6;ker</surname><given-names>M</given-names></name></person-group><article-title>List of prokaryotic names with standing in nomenclature (LPSN) moves to the DSMZ</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2020</year><volume>70</volume><fpage>5607</fpage><lpage>5612</lpage><pub-id pub-id-type="doi">10.1099/ijsem.0.004332</pub-id><pub-id pub-id-type="pmid">32701423</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanem</surname><given-names>G</given-names></name><name><surname>Adachi</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X-Y</given-names></name><name><surname>Raad</surname><given-names>I</given-names></name></person-group><article-title>Central venous catheter-related <italic>Streptomyces</italic> septic thrombosis</article-title><source>Infect. Control Hosp. Epidemiol.</source><year>2007</year><volume>28</volume><fpage>599</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1086/513619</pub-id><pub-id pub-id-type="pmid">17464923</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapadia</surname><given-names>M</given-names></name><name><surname>Rolston</surname><given-names>KVI</given-names></name><name><surname>Han</surname><given-names>XY</given-names></name></person-group><article-title>Invasive <italic>Streptomyces</italic> infections: Six cases and literature review</article-title><source>Am. J. Clin. Pathol.</source><year>2007</year><volume>127</volume><fpage>619</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1309/QJEBXP0BCGR54L15</pub-id><pub-id pub-id-type="pmid">17369139</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Scalp abscess due to <italic>Streptomyces cacaoi</italic> subsp. <italic>cacaoi</italic>, first report in a human infection</article-title><source>J. Clin. Microbiol.</source><year>2012</year><volume>50</volume><fpage>1484</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1128/JCM.06372-11</pub-id><pub-id pub-id-type="pmid">22278841</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yacoub</surname><given-names>AT</given-names></name><name><surname>Velez</surname><given-names>AP</given-names></name><name><surname>Khwaja</surname><given-names>SI</given-names></name><name><surname>Sandin</surname><given-names>RL</given-names></name><name><surname>Greene</surname><given-names>J</given-names></name></person-group><article-title><italic>Streptomyces</italic> pneumonia in an immunocompromised patient: A case report and a review of literature</article-title><source>Infect. Dis. Clin. Pract.</source><year>2014</year><volume>22</volume><fpage>2</fpage><lpage>5</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kofteridis</surname><given-names>DP</given-names></name><etal/></person-group><article-title><italic>Streptomyces</italic> pneumonia in an immunocompetent patient: A case report and literature review</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2007</year><volume>59</volume><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2007.06.009</pub-id><pub-id pub-id-type="pmid">17928185</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariza-Prota</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Community-acquired bacteremic <italic>Streptomyces atratus</italic> pneumonia in an immunocompetent adult: A case report</article-title><source>J. Med. Case Rep.</source><year>2015</year><volume>9</volume><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s13256-015-0753-y</pub-id><pub-id pub-id-type="pmid">25597932</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manteca</surname><given-names>A</given-names></name><etal/></person-group><article-title>A rare case of lung coinfection by <italic>Streptomyces cinereoruber</italic> and <italic>Haemophilus influenzae</italic> in a patient with severe chronic obstructive pulmonary disease: characterization at species level using molecular techniques</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2008</year><volume>60</volume><fpage>307</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2007.10.009</pub-id><pub-id pub-id-type="pmid">18061387</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>MC</given-names></name><name><surname>Manteca</surname><given-names>A</given-names></name><name><surname>Castillo</surname><given-names>ML</given-names></name><name><surname>V&#x000e1;zquez</surname><given-names>F</given-names></name><name><surname>M&#x000e9;ndez</surname><given-names>FJ</given-names></name></person-group><article-title><italic>Streptomyces albus</italic> isolated from a human actinomycetoma and characterized by molecular techniques</article-title><source>J. Clin. Microbiol.</source><year>2004</year><volume>42</volume><fpage>5957</fpage><lpage>5960</lpage><pub-id pub-id-type="doi">10.1128/JCM.42.12.5957-5960.2004</pub-id><pub-id pub-id-type="pmid">15583353</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>P</given-names></name><name><surname>Arora</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name><name><surname>Chander</surname><given-names>J</given-names></name><name><surname>Van De Sande</surname><given-names>W</given-names></name></person-group><article-title>Secondary peritonitis caused by <italic>Streptomyces viridis</italic></article-title><source>J. Clin. Microbiol.</source><year>2012</year><volume>50</volume><fpage>1813</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1128/JCM.06045-11</pub-id><pub-id pub-id-type="pmid">22337982</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">CLSI. Performance standards for antimicrobial susceptibility testing. 30th Ed. <italic>CLSI guidlines M100</italic><ext-link ext-link-type="uri" xlink:href="http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI">http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI</ext-link> M100 ED31:2021&#x00026;scope=user (2020).</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">EUCAST. Harmonizing of breakpoints for existing antimicrobial agents. <italic>EUCAST standard operation procedure</italic><ext-link ext-link-type="uri" xlink:href="http://www.eucast.org">www.eucast.org</ext-link> (2019).</mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Kieser, T., Bibb, M. J., Buttner, M., Chater, K. F. &#x00026; Hopwood, D. Growth and preservation of <italic>Streptomyces</italic>. <italic>Pract. Streptomyces Genet.</italic> 43&#x02013;62 (2000).</mixed-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashad</surname><given-names>FM</given-names></name><name><surname>Fathy</surname><given-names>HM</given-names></name><name><surname>El-Zayat</surname><given-names>AS</given-names></name><name><surname>Elghonaimy</surname><given-names>AM</given-names></name></person-group><article-title>Isolation and characterization of multifunctional <italic>Streptomyces</italic> species with antimicrobial, nematicidal and phytohormone activities from marine environments in Egypt</article-title><source>Microbiol. Res.</source><year>2015</year><volume>175</volume><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2015.03.002</pub-id><pub-id pub-id-type="pmid">25805507</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zothanpuia</surname><given-names>AKP</given-names></name><name><surname>Yadav</surname><given-names>MK</given-names></name><name><surname>Singh</surname><given-names>BP</given-names></name></person-group><article-title>In vitro evaluation of antimicrobial activities and antibiotic susceptibility profiling of culturable <italic>actinobacteria</italic> from fresh water streams</article-title><source>Indian J. Exp. Biol.</source><year>2018</year><volume>56</volume><fpage>665</fpage><lpage>673</lpage></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zothanpuia</surname><given-names>AKP</given-names></name><name><surname>Singh</surname><given-names>BP</given-names></name></person-group><article-title>Molecular characterization of actinomycetes isolated from Tuichang river and their biosynthetic potential</article-title><source>Sci. Vis.</source><year>2015</year><volume>15</volume><fpage>136</fpage><lpage>144</lpage></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pet&#x00159;&#x000ed;&#x0010d;kov&#x000e1;</surname><given-names>K</given-names></name><etal/></person-group><article-title>Evolution of cyclizing 5-aminolevulinate synthases in the biosynthesis of actinomycete secondary metabolites: Outcomes for genetic screening techniques</article-title><source>Front. Microbiol.</source><year>2015</year><volume>6</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2015.00814</pub-id><pub-id pub-id-type="pmid">25653648</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altschul</surname><given-names>SF</given-names></name><name><surname>Gish</surname><given-names>W</given-names></name><name><surname>Miller</surname><given-names>W</given-names></name><name><surname>Myers</surname><given-names>EW</given-names></name><name><surname>Lipman</surname><given-names>DJ</given-names></name></person-group><article-title>Basic local alignment search tool</article-title><source>J. Mol. Biol.</source><year>1990</year><volume>215</volume><fpage>403</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(05)80360-2</pub-id><pub-id pub-id-type="pmid">2231712</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labeda</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Phylogenetic study of the species within the family <italic>Streptomycetaceae</italic></article-title><source>Antonie Van Leeuwenhoek</source><year>2012</year><volume>101</volume><fpage>73</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/s10482-011-9656-0</pub-id><pub-id pub-id-type="pmid">22045019</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirling</surname><given-names>EB</given-names></name><name><surname>Gottlieb</surname><given-names>D</given-names></name></person-group><article-title>Methods for characterization of <italic>Streptomyces</italic> species</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>1966</year><volume>16</volume><fpage>313</fpage><lpage>340</lpage></element-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">CLSI. Susceptibility testing of Mycobacteria, and other aerobic Actinomycetes. 2nd edn. <italic>CLSI guidlines M24</italic> (2011).</mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">CLSI. Development of in vitro susceptibility testing criteria and quality control parameters. 2nd Ed. <italic>CLSI guidlines M23</italic> (2001).</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kronvall</surname><given-names>G</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name></person-group><article-title>Normalized resistance interpretation, the NRI method: Review of NRI disc test applications and guide to calculations</article-title><source>APMIS</source><year>2016</year><volume>124</volume><fpage>1023</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1111/apm.12624</pub-id><pub-id pub-id-type="pmid">27859688</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasher</surname><given-names>MA</given-names></name><name><surname>Hay</surname><given-names>RJ</given-names></name><name><surname>Mahgoub</surname><given-names>ES</given-names></name><name><surname>Gumaa</surname><given-names>SA</given-names></name></person-group><article-title>In vitro studies of antibiotic sensitivities of <italic>Streptomyces somaliensis</italic> a cause of human actinomycetoma</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1989</year><volume>83</volume><fpage>265</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(89)90675-5</pub-id><pub-id pub-id-type="pmid">2609384</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moss</surname><given-names>WJ</given-names></name><name><surname>Sager</surname><given-names>JA</given-names></name><name><surname>Dick</surname><given-names>JD</given-names></name><name><surname>Ruff</surname><given-names>A</given-names></name></person-group><article-title><italic>Streptomyces bikiniensis</italic> bacteremia</article-title><source>Emerg. Infect. Dis.</source><year>2003</year><volume>9</volume><fpage>273</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.3201/eid0902.020275</pub-id><pub-id pub-id-type="pmid">12604007</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqui</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fulminant mulch pneumonitis: An emergency presentation of chronic granulomatous disease</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>45</volume><fpage>673</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1086/520985</pub-id><pub-id pub-id-type="pmid">17712749</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riviere</surname><given-names>E</given-names></name><etal/></person-group><article-title>Pulmonary <italic>Streptomyces</italic> infection in patient with sarcoidosis, France, 2012</article-title><source>Emerg. Infect. Dis.</source><year>2012</year><volume>18</volume><fpage>1907</fpage><lpage>1909</lpage><pub-id pub-id-type="doi">10.3201/eid1811.120797</pub-id><pub-id pub-id-type="pmid">23092549</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kagen</surname><given-names>SL</given-names></name><name><surname>Fink</surname><given-names>JN</given-names></name><name><surname>Schlueter</surname><given-names>DP</given-names></name><name><surname>Kurup</surname><given-names>VP</given-names></name><name><surname>Fruchtman</surname><given-names>RB</given-names></name></person-group><article-title><italic>Streptomyces albus</italic>: A new cause of hypersensitivity pneumonitis</article-title><source>J. Allergy Clin. Immunol.</source><year>1981</year><volume>68</volume><fpage>295</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1016/0091-6749(81)90155-X</pub-id><pub-id pub-id-type="pmid">6793652</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Case of keratitis caused by <italic>Streptomyces thermocarboxydus</italic></article-title><source>J. Infect. Chemother.</source><year>2014</year><volume>20</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.jiac.2013.11.001</pub-id><pub-id pub-id-type="pmid">24462427</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>AS</given-names></name><name><surname>Wellington</surname><given-names>EMH</given-names></name></person-group><article-title>The taxonomy of <italic>Streptomyces</italic> and related genera</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2001</year><volume>51</volume><fpage>797</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1099/00207713-51-3-797</pub-id><pub-id pub-id-type="pmid">11411701</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogawara</surname><given-names>H</given-names></name></person-group><article-title>Self-resistance in <italic>Streptomyces</italic>, with special reference to &#x003b2;-lactam antibiotics</article-title><source>Molecules</source><year>2016</year><volume>21</volume><fpage>1</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.3390/molecules21050605</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welsh</surname><given-names>O</given-names></name><name><surname>Al-Abdely</surname><given-names>HM</given-names></name><name><surname>Salinas-Carmona</surname><given-names>MC</given-names></name><name><surname>Fahal</surname><given-names>AH</given-names></name></person-group><article-title>Mycetoma medical therapy</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0003218</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>ST</given-names></name></person-group><article-title>Sensitivity of streptomycetes</article-title><source>J. Gen. Microbiol.</source><year>1967</year><volume>46</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1099/00221287-46-1-151</pub-id><pub-id pub-id-type="pmid">4291590</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>H</given-names></name><name><surname>Ford</surname><given-names>N</given-names></name></person-group><article-title>Linezolid for the treatment of complicated drug-resistant tuberculosis: A systematic review and meta-analysis</article-title><source>Int. J. Tuberc. Lung Dis.
</source><year>2012</year><volume>16</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.5588/ijtld.11.0451</pub-id><pub-id pub-id-type="pmid">22325685</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myneedu</surname><given-names>VP</given-names></name><etal/></person-group><article-title>First and second line drug resistance among treatment na&#x000ef;ve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi</article-title><source>J. Epidemiol. Glob. Health</source><year>2015</year><volume>5</volume><fpage>365</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/j.jegh.2015.04.002</pub-id><pub-id pub-id-type="pmid">25944154</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Bene&#x00161;, J. <italic>Antibiotika: systematika, vlastnosti, pou&#x0017e;it&#x000ed;</italic>. (Grada Publishing, 2018).</mixed-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Talaska</surname><given-names>AE</given-names></name><name><surname>Schacht</surname><given-names>J</given-names></name></person-group><article-title>New developments in aminoglycoside therapy and ototoxicity</article-title><source>Hear. Res.</source><year>2011</year><volume>281</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.heares.2011.05.008</pub-id><pub-id pub-id-type="pmid">21640178</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krause</surname><given-names>KM</given-names></name><name><surname>Serio</surname><given-names>AW</given-names></name><name><surname>Kane</surname><given-names>TR</given-names></name><name><surname>Connolly</surname><given-names>LE</given-names></name></person-group><article-title>Aminoglycosides: An overview</article-title><source>Cold Spring Harb. Perspect Med.</source><year>2016</year><volume>6</volume><fpage>a027029</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a027029</pub-id><pub-id pub-id-type="pmid">27252397</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><mixed-citation publication-type="other">B&#x000e9;brov&#x000e1;, E. <italic>et al</italic>. Doporu&#x0010d;en&#x000fd; postup pro antibiotickou l&#x000e9;&#x0010d;bu komunitn&#x000ed;ch respira&#x0010d;n&#x000ed;ch infekc&#x000ed; v prim&#x000e1;rn&#x000ed; p&#x000e9;&#x0010d;i. <italic>Prakt. L&#x000e9;k.</italic><bold>83</bold>, 502&#x02013;515. <ext-link ext-link-type="uri" xlink:href="http://www.cls.cz/dokumenty/Doporuceny_postup_ATB_lecba.doc">www.cls.cz/dokumenty/Doporuceny_postup_ATB_lecba.doc</ext-link> (2003).</mixed-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>LF</given-names></name><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Kirby</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>CW</given-names></name></person-group><article-title>A multidrug efflux system is involved in colony growth in <italic>Streptomyces lividans</italic></article-title><source>Microbiology</source><year>2007</year><volume>153</volume><fpage>924</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1099/mic.0.2006/000018-0</pub-id><pub-id pub-id-type="pmid">17379703</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Characterization of an inducible vancomycin resistance system in <italic>Streptomyces coelicolor</italic> reveals a novel gene (<italic>vanK</italic>) required for drug resistance</article-title><source>Mol. Microbiol.</source><year>2004</year><volume>52</volume><fpage>1107</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2004.04032.x</pub-id><pub-id pub-id-type="pmid">15130128</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L-F</given-names></name><name><surname>Huang</surname><given-names>Y-J</given-names></name><name><surname>Chen</surname><given-names>CW</given-names></name></person-group><article-title>Repressed multidrug resistance genes in <italic>Streptomyces lividans</italic></article-title><source>Arch. Microbiol.</source><year>2003</year><volume>180</volume><fpage>176</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s00203-003-0574-z</pub-id><pub-id pub-id-type="pmid">12937892</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Versporten</surname><given-names>A</given-names></name><etal/></person-group><article-title>Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997&#x02013;2017</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>45</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab177</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adriaenssens</surname><given-names>N</given-names></name><etal/></person-group><article-title>Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997&#x02013;2017</article-title><source>J. Antimicrob. Chemother.</source><year>2021</year><volume>76</volume><fpage>30</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1093/jac/dkab175</pub-id><pub-id pub-id-type="pmid">33031488</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Fujiwara</surname><given-names>T</given-names></name><name><surname>Ochi</surname><given-names>K</given-names></name><name><surname>Hosaka</surname><given-names>T</given-names></name></person-group><article-title>Development of the ability to produce secondary metabolites in <italic>Streptomyces</italic> through the acquisition of erythromycin resistance</article-title><source>J. Antibiot. (Tokyo)</source><year>2012</year><volume>65</volume><fpage>323</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/ja.2012.16</pub-id><pub-id pub-id-type="pmid">22491137</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoshino</surname><given-names>K</given-names></name><etal/></person-group><article-title>A putative mechanism underlying secondary metabolite overproduction by <italic>Streptomyces</italic> strains with a 23S rRNA mutation conferring erythromycin resistance</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2020</year><volume>104</volume><fpage>2193</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-10288-1</pub-id><pub-id pub-id-type="pmid">31925486</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sk&#x000f6;ld</surname><given-names>O</given-names></name></person-group><article-title>Resistance to trimethoprim and sulfonamides</article-title><source>Vet. Res.</source><year>2001</year><volume>32</volume><fpage>261</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1051/vetres:2001123</pub-id><pub-id pub-id-type="pmid">11432417</pub-id></element-citation></ref></ref-list></back></article>